Received Mar 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | PO / MO |
The patient took the second dose of the Vivotif vaccine day after the first dose; Case reference number US-BN-2024-002820 is a spontaneous case initially received from a pharmacist via Med Communications (reference number: USBAV24-3133) on 26-Nov-2024 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 24-Nov-2024, the patient took the first dose of Vivotif (batch number: unknown), at a dose of one capsule, orally, for unknown indication. On 25-Nov-2024, one day after the first dose, the patient took the second dose of Vivotif (batch number: unknown), at a dose of one capsule orally (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20241126-572032 to US-BAVARIAN NORDIC A/S-US-BN-2024-002820, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A female patient of unspecified age took the second dose of Vivotif (at a dose of one capsule orally) one day after the first dose which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to the Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A female patient of unspecified age took the second dose of Vivotif (at a dose of one capsule orally) one day after the first dose which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to the Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None